Publicacións (42) Publicacións de JOSÉ MANUEL MARTÍNEZ SESMERO

2024

  1. Comparación de la calidad de vida en personas que viven con infección por VIH en seguimiento mediante atención farmacéutica según metodología capacidad motivación-oportunidad vs. seguimiento convencional. Proyecto MAS-VIH

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 2, pp. 149-157

2023

  1. Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 10, pp. 589-595

  2. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients

    BMC Health Services Research, Vol. 23, Núm. 1

  3. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

    PharmacoEconomics - Open, Vol. 7, Núm. 3, pp. 431-441

  4. Terapia celular

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 129-135

2022

  1. Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

    Global and Regional Health Technology Assessment, Vol. 9, pp. 68-72

  2. Business intelligence for the visualization and data analysis of Telepharmacy activity indicators in a hospital pharmacy service scorecard

    Farmacia Hospitalaria, Vol. 46, pp. 24-30

  3. Contribución de cabotegravir + rilpivirina de acción prolongada al tratamiento de la infección por VIH-1

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 208-214

  4. Past and future of HIV infection. A document based on expert opinion

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 35, Núm. 2, pp. 131-156

  5. Patient Experience Evaluation of the CMO-Based Pharmaceutical Care Model vs Usual Care in People Living with HIV

    Journal of Multidisciplinary Healthcare, Vol. 15, pp. 2991-3003

2021

  1. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 5, pp. 967-973

  2. How do hospital pharmacists approach substitution of nanomedicines? Insights from a qualitative pilot study and a quantitative market research analysis in five european countries

    Pharmaceutics, Vol. 13, Núm. 7

  3. IMPACT OF ANTIHYPERTENSIVE TREATMENT IN COVID-19 PATIENTS IN A TERTIARY CARE HOSPITAL

    European Journal of Clinical Pharmacy, Vol. 23, Núm. 4, pp. 220-225

  4. Metodología de la comparación indirecta ajustada con emparejamiento en la evaluación de fármacos hematooncológicos

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 2, pp. 55-60

2020

  1. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

    PharmacoEconomics - Open, Vol. 4, Núm. 4, pp. 615-624

  2. Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: Current situation, challenges, and opportunities

    Farmacia Hospitalaria, Vol. 44, Núm. 3, pp. 100-108

  3. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain

    Clinical Rheumatology, Vol. 39, Núm. 10, pp. 2919-2930

  4. Gestión integral de la nutrición artificial domiciliaria: humanización e innovación al servicio del paciente

    Anales de la Real Academia Nacional de Farmacia, Vol. 86, Núm. 4, pp. 257-268

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 465-475